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Synopsis
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The dose-exposure-response relationship for drugs may differ in pediatric patients compared to
adults due to developmental changes in processes involved in drug disposition (absorption,
distribution, metabolism and excretion) and drug response. This relative knowledge deficit has
complicated drug efficacy and safety labeling of drugs for pediatric use. With the legislative
changes that have occurred in the US and Europe over the last 20 years, many clinical studies have
been conducted to establish drug dose-exposure relationships across the pediatric age spectrum
from birth to adolescence. However, genetic variation has seldom been included in these
investigations. This article applies a systematic approach to determine the relative contribution of
development and genetic variation on drug disposition and response using HMG-CoA reductase
inhibitors as a model. Application of the approach drives the collection of information relevant to
understanding the potential contribution of ontogeny and genetic variation to statin dose-exposureresponse in children, and identifies important knowledge deficits to be addressed through the
design of future studies.
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There has been extensive reform in pediatric drug labeling accomplished over the last twenty
years as a direct result of new federal laws and regulation. In 1994, the US Food and Drug
Administration (FDA) called for drug manufacturers to determine if existing data was
sufficient for pediatric drug labeling1. Participation in this endeavor was subpar and
therefore, the FDA Modernization Act (FDAMA) was enacted in November 1997. This
legislation provided an additional six month patent exclusivity to manufacturers that conduct
pediatric clinical trials according the FDA parameters2. A detailed review of the
chronological events from 1994–2002 are provided by Steinbrook3. In January 2002, the
Best Pharmaceuticals for Children Act (BPCA) provided further opportunities for drug
manufacturers to generate data on drugs that were off-patent or patented drugs that has not
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been studied in children4. One year later, the Pediatric Research Equity Act (PREA) enabled
the FDA to require pediatric studies5. Overall, the results from this legislation have led to
dramatic increase in pediatric studies on greater than 300 drugs and biological products. The
plethora of new information has illuminated the continued challenge of appropriate pediatric
drug dosing, efficacy, and safety.

Author Manuscript

As is widely appreciated in pediatric medicine, the changes that occur as children grow and
develop influence the diagnosis and treatment of clinical disease. Merely extrapolating from
adult therapeutic data may overlook the influence that developmental changes in expression
of genes responsible for drug disposition have on dosing requirements and safety profiles of
drugs that have distinct variation from birth until adulthood. Pharmacotherapy in children,
like adults, is dependent upon clear understanding of the dose-exposure-response
relationship of the drug to be administered. However, extrapolation of adult experience to
pediatric age groups is complicated by age-associated differences in pharmacokinetics of
several drugs used clinically in children6. In the past decade ontogeny of drug disposition,
specifically in the domain of hepatic drug metabolizing enzymes, has been discovered7.
However, our understanding of genetic variation’s impact on drug disposition and efficacy in
pediatrics still is lacking8, 9. As expected though, the difficulty in performing prospective
pediatric studies, due to ethical challenges and/or inadequate participation, have limited this
greater understanding.

Author Manuscript

Understanding the relative contribution of ontogeny and genetic variation to observed
variability in drug disposition and response in children challenges all parties involved in
pediatrics drug research. The implementation of pharmacogenetic and pharmacogenomic
strategies in children serves as another barrier to improve pediatric drug therapeutics. In the
absence of more comprehensive data, a systematic approach has been developed to gather
more information about certain drugs, identify knowledge gaps, and design studies to
address those deficits. This approach has been used previously to address the dilemma of
over the counter cough and cold preparations10. Our goal in this paper is to illustrate the use
this systematic approach to assess current knowledge regarding the effects of ontogeny and
genetic variation on the dose-exposure-response of a drug class whose use in pediatrics is
anticipated to increase in the near future.

Evolution of Statin Therapy in Children

Author Manuscript

Cardiovascular disease remains the number one cause of mortality in the United States
despite significant progress in medical and invasive treatments11. Although symptoms
typically appear in the 5th and 6th decades of life, atherosclerotic coronary artery disease
(CAD) has its origins in childhood. In 1953, autopsies performed on 300 U.S. servicemen in
their 20’s revealed that over 75% had evidence of coronary atherosclerosis12. Another
autopsy study of U.S. soldiers killed in the Vietnam War showed a 45% rate of
atherosclerosis13. In a subsequent study involving young children and adolescents, fatty
streaks, clinically silent precursors to CAD, were observed in the aortas of all children after
the age of 3 years and progressed rapidly to coronary involvement by adolescence.
Advancement to fibrous plaques mostly occurred in the third to fourth decades14. The
Pathobiological Determinants of Atherosclerosis in Youth study and the Bogalusa Heart
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Study noted varying stages of atherosclerosis in young children and youth with elevated
low-density lipoprotein cholesterol (LDL) and other risk factors such as obesity,
hypertension, tobacco smoke exposure and diabetes15, 16. These landmark studies have
highlighted the need for implementing lipid screening and preventive cardiovascular
measures during childhood.

Author Manuscript

The prevalence of total cholesterol (TC) >200mg/dl has risen to 10% in adolescents17.
Epidemiological studies have documented that 75% of children with a TC concentration
greater than the 90th percentile have TC concentrations >200mg/dl in their early twenties18.
Elevated cholesterol is commonly associated with being overweight or obese. An alarming
one-third of 2 to 19 year olds in the United States are diagnosed as overweight with a body
mass index greater than the 85th percentile for age and sex19. A 55-year observational study
showed that being overweight in adolescence resulted in a 2 fold higher relative risk of CAD
mortality, independent of adult weight20. With the increasing prevalence of overweight
children, the prevalence of clinically diagnosed CAD in young to middle age adults is
expected to increase by 5–16% by the year 203521.

Author Manuscript

In 1992, the National Cholesterol Education Program recommended lipid screening for
children with a family history of premature CAD or dyslipidemia and in children with other
risk factors such as obesity, hypertension, and diabetes mellitus22. This screening strategy
has uncovered more cases of subclinical dyslipidemia that, without screening, would have
been unrecognized for decades. More recent data have revealed that using family history
alone to select children for lipid screening misses many patients with moderate acquired
dyslipidemia and genetic dyslipidemia who may require pharmacologic treatment23.
Therefore, updated guidelines from the American Academy of Pediatrics now recommend
universal lipid screening at ages 9 to 11 years, and again at ages 18 to 21 years24.

Author Manuscript

Treatment strategies for dyslipidemia, including lifestyle modifications and pharmacologic
therapy, have been well established in adults. In those who fail lifestyle modifications,
pharmacologic therapy is commonly implemented. Guidelines for diet and pharmacologic
treatment in children have also been established24, 25. There are several classes of
medication available for treatment of dyslipidemia. 3-Hydroxy-3-methyl-glutaryl Coenzyme
A (HMG-CoA) reductase inhibitors (statins) are now the mainstay of pharmacologic
treatment of adult and pediatric dyslipidemia due to their demonstrated efficacy in the
primary and secondary prevention of coronary artery disease and relatively mild side effect
profile26–30. HMG-CoA reductase inhibitors decrease the hepatic synthesis of cholesterol by
blocking the conversion of HMG-CoA to mevalonate, which is the rate-limiting step in
cholesterol synthesis (Figure 1). The LDL-C receptor genes respond to this decrease of
intracellular sterol by upregulating cell-surface LDL-C receptor expression31, which
ultimately decreases the serum LDL. Furthermore, statins’ pleiotropic effects include the
decrease of inflammatory mediators downstream from HMG-CoA reductase. This
pleiotropic effect could ultimately provide efficacy in other disorders of childhood
inflammation beyond the scope of dyslipidemia. For example, patients with sickle cell
disease can develop oxidative stress and chronic inflammation to their distal vasculature as a
result of transient vaso-occlusion and subsequent reperfusion injury32. Hoppe et al found
that biomarkers of vascular dysfunction, including C-reactive protein and interleukin 6, were
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decreased in adolescents with sickle cell disease from 50% up to 70% after a 3 week trial of
low (20 mg) or moderate (40mg) doses of simvastatin33. Additionally, statins have been
utilized after cardiac transplantation to prevent coronary allograft vasculopathy (CAV). In
pediatric cardiac transplantation, the prevalance of CAV is less pronounced compared to
adults, but has been reported to be as high as 17% in one retrospective analysis34. LDL
levels >100mg/dl, greater than optimal and near adult treatment range, have been reported in
39% of pediatric patients 1 year after transplantation35, which can be secondary to posttransplant steroid and cyclosporine therapy. Addition of pravastatin therapy in pediatric
cardiac transplant recipients yielded a lower incidence of CAV34. Overall, statins are usually
well tolerated and result in a 20–50% reduction in cholesterol from baseline36. Available
information on statin use in pediatrics implies that statins are being used conservatively in
children, estimated to be 1:4,500 children37. However, this crude estimate is likely to
underestimate current use as it is derived from an analysis of Medicaid data from 2000 and a
commercial Caremark database from 200438, and preceded the increase in obesity and type
II diabetes in children that has occurred over the past decade.

Author Manuscript

There are currently seven FDA approved statins - lovastatin, simvastatin, pravastatin,
fluvastatin, atorvastatin, rosuvastatin, and pitavastatin. The majority of statin trials in
pediatric subjects have involved lovastatin, simvastatin, and pravastatin28. Lovastatin, the
first statin developed in the late 1980s, is a lipophilic, semi-synthetic inhibitor of HMG-CoA
reductase. It is administered as an inactive lactone prodrug and is hydrolyzed in the liver to
its active metabolites39. Simvastatin, introduced in the early 1990s, is also a lipophilic, semisynthetic inhibitor of HMG-CoA reductase and administered as an inactive lactone prodrug
that undergoes carboxylesterase-mediated conversion in the plasma, liver and intestine to
simvastatin acid, which is the active metabolite40. Pravastatin, introduced in the early 1990s,
is a hydrophilic, semi-synthetic inhibitor of HMG-CoA reductase41. Due to its hydrophilic
nature, it fails to cross the blood brain barrier, making it a potentially safer alternative for
maturing brains in children. Unlike other statins, it is not significantly metabolized by
cytochrome P450 enzymes. In fact, the major metabolites are mainly produced in the acidic
conditions of the stomach and are inactive42.

Author Manuscript

The majority of pediatric trials have focused on efficacy of lipid lowering and safety. The
most recent double-blind, randomized, placebo-controlled, multicenter trial involving
lovastatin (20 mg until week 4 then 40 mg from week 5 until week 24) in 54 postmenarchal
females with familial hyperlipidemia between the ages of 10 to 17 years demonstrated a
23% reduction in LDL at 4 weeks and 27% after 24 weeks of treatment. Additionally, there
were no clinically significant adverse effects observed between the two treatment groups
over a 6 month period43. The largest double-blind, randomized, placebo-controlled multicenter trial with simvastatin (10 mg titrating up to 40 mg by week 24 continuing until week
48) in children ages 10 to 17 years by de Jongh et al demonstrated a 41% reduction in LDL,
displaying simvastatin’s efficacy in LDL reduction in children as well. There was a small
decrease in dehydroepiandrosterone sulfate (DHEA) compared to subjects taking placebo,
but no other changes in adrenal, gonadal, or pituitary hormones were observed in the
treatment or placebo groups. No serious adverse drug events were reported in either
treatment group44. Three previous double blind, randomized, placebo-controlled trials have
demonstrated an approximate 25–35% reduction in LDL with pravastatin use in children,
Pediatr Clin North Am. Author manuscript; available in PMC 2018 March 12.
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validating its efficacy in this age group41, 45, 46. In addition to lowering LDL and total
cholesterol, there is evidence that statin therapy in children with dyslipidemia can reverse
increased carotid intima-medial thickness (IMT) and arterial endothelial dysfunction
measured by ultrasound and flow-medaited dilation, respectively46, 47, which are biomarkers
of the atherosclerotic process48–54. However, the studies presented above all involved a fixed
dose of statin medication, and the effective dose received by each subject (mg per kg) would
be expected to vary across the population, and the variability in dose administered alone
could contribute to variability in response. For instance, de Jongh et al reported a mean
decrease of 41% LDL cholesterol with a standard deviation of 39.2% at 48 weeks of
simvastatin therapy44, and Wiegman et al reported that pravastatin was associated with a
mean decrease in LDL of 24% with a range of 7–41%46. It is likely that additional factors,
specifically ontogeny and genetic variation, will also contribute to variability in statin
disposition and response in pediatric patients. These factors are discussed in more detail
below.

Contributions of Ontogeny and Genetic Variation in Drug Disposition

Author Manuscript

The relative lack of data regarding pediatric drug disposition is a limiting factor for optimal
pediatric drug dosing strategies to maximize efficacy and minimize the potential for toxicity.
Given that the use of statins can be anticipated to increase as a result of mandatory screening
programs and difficulty with adherence to dietary and behavioral modifications, the pediatric
community should be proactive in establishing therapeutic guidelines before statins are in
widespread use. These therapeutic guidelines should be based on solid information
concerning the dose-exposure-response relationship in pediatric patients, and studies
designed to generate this information should take advantage of existing knowledge related to
the contributions of ontogeny and genetic variation. The purpose of the remainder of this
review is to present three fundamental issues that should be considered when assimilating
current knowledge for application to problems related to variability in drug disposition and
response in children. This systematic approach is applied to identify knowledge deficits
related to the contribution of ontogeny and genetic variation to impact statin disposition and
response in children, with implications for the design of future studies to address these
knowledge deficits.
Fundamental issues for assessing variability in drug disposition in children

Author Manuscript

1. Knowledge of gene products that are quantitatively important in the
disposition (absorption, distribution, metabolism, and excretion) of the
drug(s) of interest?—Simvastatin and lovastatin have been the two of the most
commonly studied HMG-CoA reductase inhibitors in the pediatric population. They are both
semi-synthetic, lipophilic compounds administered as a lactone prodrugs39, 55 that are
mainly absorbed from the gastrointestinal tract via passive diffusion and are subsequently
hydrolyzed to active beta-hydroxy acid forms, simvastatin acid or lovastatin acid, in the
liver39. In vivo, approximately 60–85% of the simvastatin prodrug is absorbed in the
stomach, whereas only 30% of lovastatin prodrug is absorbed39, 56, 57. Due to their lipophilic
nature, simvastatin and lovastatin are >95% protein bound in the plasma. Fluvastatin,
atorvastatin, and pitavastatin are synthetic, lipophilic (although less than simvastatin and
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lovastatin) compounds administered in their active form. They are absorbed rapidly via
passive diffusion in the gastrointestinal tract secondary to their lipophilic nature and have a
bioavailbility of 30%, 12%, 51%, respectively. They are also highly protein bound due to
their lipophilic nature39, 56, 58. Pravastatin remains a popular statin used in childhood and is
labeled for use in children greater than 8 years of age. It is a hydrophilic, semi-synthetic
compound that is administered in its active acidic form. Gastrointestinal absorption is
estimated to be 30–35% due to its highly hydrophilic nature and reduced passive diffusion;
absolute bioavailability is lower (17–18%) as a consequence of this incomplete absorption
and first-pass metabolism. Due to its hydrophilic nature, it is only 50% protein bound39, 56.
Rosuvstatin is a synthetic, hydrophilic (although less than pravstatin) compound that is
administered in its active form. It also undergoes a slower absorption phase due to its less
lipophilic nature, but protein bound is greater relative to pravstatin59, 60.

Author Manuscript
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The liver is the major site of action and clearance for all statins used clinically. Hepatic
uptake of statins is mediated by influx transporters known as organic anion transporting
polypeptides (OATPs; Phase 0), followed by cytochrome P450 (CYP)-mediated oxidative
metabolism for most statins (Phase 1), conjugation with glucuronic acid (Phase 2), and
excretion of conjugated metabolites in the bile via the MRP family of efflux transporters
(Phase 3)56, 61. These processes are summarized in Figure 2. Theoretically, any of these
steps could be rate-limiting for statin clearance, but animal studies indicate that more
comprehensive models that include hepatic uptake are superior to models based on
metabolism alone in predicting in vivo statin clearance from in vitro systems62. Each of
these four steps of statin disposition in liver will be discussed in more detail below.
Emphasis will be paid to those processes that are quantitatively important in hepatic statin
disposition to distinguish those processes that profoundly affect systemic statin exposure in
humans from those that are merely capable of transporting or metabolizing statins based on
data from isolated in vitro systems.

Author Manuscript

Hepatic uptake: Although statins may gain entry to hepatocytes by passive diffusion, the
process is facilitated by a transporter-mediated system. The primary transporter mediating
the hepatotocellular uptake of statins is OATP1B1, the protein product of the SLCO1B1
gene, and has been the subject of several comprehensive reviews56, 61, 63. For pitavastatin,
OATP1B3 (SLCO1B3 gene product) has been reported to play a minor role, but uptake
primarily occurs by OATP1B1-mediated transport61, 64. Additionally, fluvastatin and
rosuvastatin have been shown to be substrates of OATP1B3 and OATP2B1 mediated
transport63, 65, 66. Although simvastatin and lovastatin can inhibit OATP1B1-mediated
transport67, OATP1B1appears less important for cellular uptake of these agents relative to
other statins due to their highly lipophilic nature and greater role for passive diffusion68.
Inhibitors of OATP1B1 are of great utility to gain insight into the functional importance of
OATP1B1 mediated statin uptake. For example, concurrent administration of a potent
inhibitor of OATP1B1 would be expected to increase the systemic exposure (as determined
by an increase in total area under the curve, or AUC) for those statins that rely on OATP1B1
for hepatic drug uptake. Theoretically, the greater the increase in AUC in the presence of
inhibitor, the greater the role of OATP1B1 in mediating hepatic drug uptake as reduced entry
into the liver is accompanied by an increase in the statin concentration circulating in plasma;
Pediatr Clin North Am. Author manuscript; available in PMC 2018 March 12.
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if a particular statin is not dependent on OATP1B1 for cellular uptake, the AUC will not be
affected by the presence of an inhibitor. The quantitative importance of OATP1B1 for statin
uptake in vivo has been established using rifampin, a known inhibitor of OATP1B1 and
OATP1B3 in vitro. For example, concurrent administration of a single 600 mg dose of
rifampin resulted in a 6-fold increase in the AUC of atorvastatin acid compared to
atorvastatin alone69. Cyclosporine, a potent inhibitor of OATP1B1 and CYP3A4, increased
atorvastatin AUC 7- to 15-fold, fluvastatin AUC 3- to 4-fold, lovastatin AUC 20-fold,
pravastatin AUC 5- to 10-fold, pitavastatin AUC 5-fold, rosuvstatin AUC 7-fold, and
simvastatin AUC 3- to 8-fold (reviewed in63). The potential contribution of CYP3A4
inhibition to the increased AUC of statins associated with cyclosporine is considered to be
minor at best given that rosuvstatin, pravastatin, and pitavastatin are excreted unchanged and
are not significantly metabolized by CYP3A470. Pravastatin, a very hydrophilic compound
that does not have significant passive diffusion capabilities, had a 10-fold increase in AUC
when given in pediatric patient on immunosuppressive therapy containing cyclosporine
compared to patients receiving pravastatin for familial hypercholesterolemia71, documenting
the importance of OATP1B1-mediated transport of pravastatin into the hepatocyte. The
effect of cyclosporine on rosuvastatin AUC (7-fold increase), another hydrophilic
compound, is consistent with an important role for OATP1B1 in hepatic uptake72.
Cumulatively, the data from studies with inhibitor studies provide convincing evidence that
the OATP1B1 transporter is a critically important determinant of drug disposition for most
of the statins. This quantitative importance of SLCO1B1 is also confirmed by
pharmacogenetics studies to be described below.

Author Manuscript
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Phase 1 metabolism: Current evidence indicates that cytochrome P450 3A4 (CYP3A4) is
the primary pathway for statin metabolism. Exception s include pravastatin, pitavastatin and
rosuvastatin, which do not undergo significant CYP-mediated metabolism58, 61, 64, and
fluvastatin, which is a substrate for CYP2C9, based on both in vitro and in vivo data73–75.
Although in vitro reaction phenotyping studies suggest that CYPs 2C8, 2C9, 2C19, 2D6,
3A4, and 3A5 are capable of metabolizing various statins, CYP3A4 appears to be primarily
responsible for the metabolism of simvastatin, lovastatin, and atorvastatin76–78, with
CYP2C8 contributing to the metabolism of some statins. The quantitative importance of
CYP3A4-dependent metabolism is illustrated by a 90% decrease in simvastatin acid
metabolism in the presence of CYP3A4/5 inhibitor troleandomycin in vitro78, and by in vivo
pharmacokinetic studies in which concurrent administration of CYP3A4 inhibitors such as
itraconazole results in 15- to 19-fold increases simvastatin and lovastatin AUC56, 79–81. A
more modest 47% increase in atorvastatin AUC is observed with co-adminstered
itraconazole82. Administration of CYP3A4 inhibitors has no significant effect on clearance
of pravastatin, fluvastatin, rosuvastatin, or pitavastatin, consistent with the limited role of
CYP3A4 in the metabolism of these compounds70.
Phase 2 metabolism: Conjugation by conjugation with glucuronic acid catalyzed by UDP
glucuronosyl transferases (UGTs) is the primary route by which statins and statin
metabolites are further metabolized in hepatocytes83, 84. The open acid forms of the statins
are glucuronidated by UGT to form an acyl glucuronide that subsequently cyclizes to form a
lactone ring. This process of lactonization is a common metabolic pathway for all statins in
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the open acid form, and results in a loss of pharmacologic activity. Statin lactones can be
converted back to the open acid forms by carboxyl esterase and subject to further
metabolism or excretion into the urine or bile; lactones can also be directly metabolized by
cytochrome P45061. Fujino et al demonstrated that the statin lactones are more rapidly
metabolized by cytochrome P450 than the statin open acids85. Concurrent administration of
gemfibrozil, a fibrate that inhibits cytochrome P450 and UGT-mediated metabolism of
simvastatin and atorvastatin, has been reported to increase the AUC of simvastatin acid, but
not the lactone form, consistent with an inhibitory effect on the lactonization of simvastatin
acid in vivo86. Overall, the contribution of UGT-dependent metabolism is considered to be
substantially less than the role of CYPs85. Other statins, such as pravastatin, rosuvastatin,
and pitavastatin, undergo excretion in their intact form and do not undergo extensive
cytochrome P450 or UGT-mediated metabolism.

Author Manuscript

Phase 3 cellular efflux: Efflux of the conjugated statin metabolites occurs via several efflux
transporters located on the canalicular membrane of the hepatocyte (Figure 2). The biliary
excretion of statins is mediated by multiple transporters, including multidrug resistance
associated protein 2 (MRP2; ABCC2), multidrug resistance 1 (MDR1; ABCB1), breast
cancer resistance protein (BCRP; ABCG2), and bile salt exporting pump (BSEP; ABCB11).
There is insufficient information to determine the quantitative importance of efflux
transporters as determinants of the systemic exposure to statins.

Author Manuscript

When all phases of hepatocellular uptake and metabolism are considered, OATP1B1 appears
to be a crucial determinant of statin drug disposition. Furthermore, CYP3A4 activity, and to
a lesser extent CYP2C8, contribute to the disposition of statins that are substrates for CYPmediated metabolism (e.g., simvastatin, lovastatin, and atorvastatin). However, when a
clinical cassette microdosing study study design was employed to investigate the relative
contribution of OATP1B1 and CYP3A4 toward atorvastatin disposition, AUC was increased
12-fold following inhibition of OATP1B1 by rifampin, but was unaffected by inhibition of
CYP3A4 by itraconazole87. Thus, hepatic uptake by OATP1B1 appears to be the ratelimiting step in atorvastatin hepatic clearance.

Author Manuscript

2. Identification of allelic variation in the genes of interest that are associated
with functional consequences in vivo?—The solute carrier organic anion transporter
(SLCO) gene family codes for OATP transporters88, and the effect of genetic variation on
statin disposition has been the subject of considerable interest63. SLCO1B1 is expressed
exclusively in the liver and its major role is drug and xenobiotic transport into the
hepatocyte. The observation of extreme "high outliers" (n=4 of 84 healthy male volunteers)
in a pharmacokinetic study of pravastatin89 was subsequently attributed to two single
nucleotide variants (SNVs) in SLCO1B1, −11187G>A in the promoter region and c.521T>C
in exon 5, which were associated with a 50% reduction of non-renal clearance90. This effect
was independently confirmed by haplotype analysis, in which heterozygous carriers of
SLCO1B1*15B (containing the 388A>G and 521T>C variants) had a mean pravastatin AUC
0–12 hours that was 93% higher compared to non-carriers, and heterozygous carriers of the
*17 haplotype (containing the −11187G>A, 388A>G and 521T>C variants) had 130%
higher AUC compared to non-carriers91. Multiple SLCO1B1 haplotypes have now been
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described and haplotype frequencies vary across geographical regions. The combined
frequency of low activity SLCO1B1*5 and *15 haplotypes is 15–20% in Europeans, 10–
15% in Asians, and approximately 2% in sub-Saharan Africans, whereas the *1B haplotype,
which is generally considered to be associated with higher activity, ranges in frequency from
26% in Europens to up to 77% in sub-Saharan Africans63. The functional consequence of
SLCO1B1 haplotype on statin AUC generally follows the dependence of individual statins
on OATP1B1 for cellular uptake. Heterozygosity for SLCO1B1*5 and *15 haplotypes is
associated with an approximately 3-fold increase in AUC for simvastatin acid, and 2.5-fold
and 2-fold increases for atorvastatin and pravastatin, respectively; fluvastatin AUC appears
to be least affected by SLCO1B1 genotype63. The effect of rifampin on atorvastatin AUC is
also dependent upon SLCO1B1 genotype with a 9-fold increase in AUC associated with the
fully functional SLCO1B1 521CC genotype compared to a 4-fold increase in AUC in
subjects homozygous for the 521TT genotype associated with reduced transporter
expression92. Thus, pharmacogenetic studies support a critical role for OATP1B1/SLCO1B1
in statin disposition.
Allelic variation in SLCO1B1 has important implications for drug safety as the increased
systemic exposure associated with reduced activity haplotypes has the potential to increase
the risk of myopathy in statin-treated patients. This relationship has been demonstrated by
the STRENGTH (Statin Response Examined by Genetic Haplotype Markers) trial in which
heterozygosity for a non-coding SNV in linkage disequilibrium with c.521T>C SNV was
associated with a 4.5-fold increase in risk of myopathy, and increase to 16.9 in subjects
homozygous for the SNV93.
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The relationship between genetic variation in phase 1 metabolism and statin disposition is
limited relative to SLCO1B1 pharmacogenetics and cellular uptake. Although CYP3A4
activity is highly variable in humans, genetic determinants of the observed variability remain
unclear94. Recently, Wang et al identified an SNV in intron 6 of CYP3A4 (rs35599367 C>T)
that has now been designated the CYP3A4*22 allele. This variant was associated with 1.7and 2.5-fold decreases in CYP3A4 expression and activity in heterozygous and homozygous
carriers, respectively. In patients receiving stable doses of either atorvastatin, simvastatin,
and lovastatin, individuals with a CYP3A4*22 allele required a 0.2–0.6-fold lower dose of
statin therapy for lipid control95, consistent with decreased CYP3A4 activity and reduced
statin clearance. This effect has been replicated by Elens et al who studied 80 patients
treated with simvastatin and observed that patients either homozygous or heterozygous for
CYP3A4*22 had a 0.25mmol/l and 0.29mmol/l reduction in total and LDL cholesterol,
respectively, compared to those with homozygous wild type96. Thus, allelic variation in
CYP3A4 also appears to influence the pharmacodynamic impact of statins that are
dependent upon this CYP for their metabolism. The CYP2C9*3 allele has a much more
dramatic effect on CYP2C9 activity, and patients homozygous for the *3 allele had 3-fold
lower clearance of the active fluvastatin enantiomer, but reduction in serum cholesterol was
not related to CYP2C9 genotype97.
Although phase 2 metabolism has a more limited impact on statin disposition compared to
cellular uptake or phase 1 metabolism, recent work suggests that UGT allelic variants may
have a modest effect of statin activity. Lactonization of atorvastatin has been attributed to
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UGT1A3, and the UGT1A3*2 allele has been associated with increased lactonization
activity98. The lactone has reduced clinical effect, and a study conducted in 23 healthy
volunteers demonstrated that homozygosity of the UGT1A3*2 allele was accompanied by a
1.7- and 2.7-fold increase in AUC of atorvastatin lactone and 2-hydroxyatorvastatin lactone,
respectively, compared to those homozygous for UGT1A3*1 allele. Furthermore, increase
lactone formation correlated with a decreased effect on total and LDL cholesterol lowering
from baseline99.

Author Manuscript

The functional consequence of genetic variation in phase 3 efflux transporters is limited
relative to the role of cellular uptake. Studies of allelic variation in ABCC2 reveal a
dependence on SLCO1B1 genotype100. Allelic variation in ABCB1 does not appear to have
any significant role in the interindividual variability in the pharmacokinetics of fluvastatin,
pravastatin, lovastatin, and rosuvastatin101. The ABCG2 c.421C>A variant has been
associated with reduced transport activity in vitro102, and the AUC of atorvastatin,
fluvastatin, simvastatin lactone, and rosuvastatin is reported to be 72%, 72%, 111% and
144% greater in subjects with a c.421AA genotype compared to wild –type c.421CC
genotype group103, 104, but no significant impact on simvastatin acid or pravastatin
pharmacokinetics103.
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3. Knowledge of the developmental profile (ontogeny) of key pathways
involved in drug disposition?—As presented above, SLCO1B1 and CYP3A4 have
emerged as the primary determinants of statin disposition based on studies conducted in
adults. Relative to drug metabolism, considerably less is known about the ontogeny of
transporters (influx and efflux) during human development. Nevertheless, knowledge of
ontogeny is essential for proper application and interpretation of pharmacogenetic data as
genotype-phenotype relationships are only apparent once the gene is expressed, and are most
stable when the gene is fully expressed. A comprehensive analysis of transporter mRNA
expression in mice of different ages and developmental stages using next generation mRNA
sequencing analysis revealed that the expression of transporters in liver is both age- and
isoform-specific105. Of the 15 SLCO genes in mice, only five were expressed in liver, with
two (Slco1a4 and Slco1b2) being included in an adolescent-enriched group of transcripts,
and three (Slco1a1, Slco2a1 and Slco2b1) have adult-enriched patterns of expression.
Slco1b2 is considered to be the mouse homolog of human SLCO1B1 and SLCO1B3, and
showed a biphasic developmental profile with expression increaseing rapidly after birth,
peaking during adolescence (10–20 days postnatal age) and declining during the transition
from adolescence to adulthood before eventually returning to adolescent levels of
expression. The ontogeny of SLCO1B1 in humans is not known, but if its ontogeny is as
complex as mouse Oatp1b2, the functional consequence of SLCO1B1 genetic variation in
children may be difficult to across the developmental spectrum. Indeed, only one small
pharmacokinetic/pharmacogenetic trial in children has been published to date. In 21 children
with familial hyperlipidemia who received pravastatin, the SLCO1B1 −11187GA genotype
appeared to have the opposite effect from that observed in adults. Children with the variant
SNV had an 81% lower peak pravastatin concentration (Cmax) and 74% lower AUC
compared to children with the wild type (−11187GG) genotype in marked contrast to
published adult experience in which the variant genotype was associated with higher AUC
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values. Additionally, patients with the c.521T>C genotype had a 49% lower peak plasma
pravastatin concentration and 26% lower AUC, but these differences did not achieve
statistical significance106. This study suffers from a small number of children with the
variant genotype, and genotype-phenotype relationships could also be confounded by
concurrent administration of cyclosporine in the cardiac transplant patients included in the
study. However, the changes in Cmax and AUC are opposite to what would be expected if
cyclosporine was inhibiting residual transporter function in patients with the variant
genotypes. Clearly, these preliminary findings need to be replicated in a larger group of
patients, and the potential effect of age (ontgen) taken into consideration.
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The ontogeny of CYPs and UGTs in humans appears to occur in distinct patterns7. CYP3A4
is a member of a gene locus that contains three other members, CYP3A5, CYP3A7 and
CYP3A43. The ontogeny of CYP3A7 is characteristic of the Group 1 pattern of expression
proposed by Hines – high expression in fetal liver followed by decreasing expression after
birth, and minimal expression in adults. CYP3A5 protein and activity can be detected in
fetal and postnatal liver, and genetic variation is a more important determinant of variability
in expression than ontogeny. The developmental trajectory of CYP3A4 follows the Group 3
pattern of expression in which functional CYP3A4 activity is minimal in fetal liver, but
increases after birth. In vitro studies conducted with a large panel of postmortem pediatric
liver tissues indicates that CYP3A7 activity in the first week of postnatal life is comparable
to that observed in fetal liver, and declines by an order of magnitude over the first year of
life. In contrast, CYP3A4 activity is low at birth, demonstrates modest increases in activity
over the first month, but remains less than that observed in adult level between 1 and 10
years of age107. These in vitro data imply that CYP3A7 may be the dominant CYP3A
isoform in the first year of life, with CYP3A4 assuming increasing importance thereafter. In
vivo data are consistent with acquisition of functional CYP3A4 activity after birth and
through the first year of life. Pharmacokinetic studies with midazolam, which is considered
to be a prototypic CYP3A4 substrate, and cisapride in neonates, consistently indicate that
clearance increases with postnatal age108. Similarly, an investigation of sildenafil
pharmacoketics in newborns revealed that a 3-fold increase in drug clearance over the first
week of life was accompanied by an increase in the formation of the CYP3A4-dependent Ndesmethyl metabolite109. A longitudinal phenotyping study conducted in infants 2 weeks to
12 months of age also supported maturation of CYP3A4 through an increase in Ndemethylated metabolites of the cough suppressant dextromethorphan110. Estimates of
weight-adjusted drug clearance (ml/min/kg) for CYP3A4 substrates generally are higher in
younger children necessitating higher weight-adjusted (mg/kg) doses than adults to achieve
similar target concentrations108. However, these differences tend to less pronounced when
clearance (and dose) are adjusted for body surface area. For example, allometric scaling of
sildenafil clearance indicates that adult levels are achieved by the end of the first week of
life109. Complicating a clearer understanding of the ontogeny of drug metabolism is the fact
that liver mass as a percentage of total body mass changes throughout childhood, being
higher (3.5%, range 2.1% to 4.7%) in children 2 years of age compared to 2.2% (range 1.8%
to 2.8%) in individuals over 18 years of age111. The issue of ontogeny is further confounded
by possibility that the pattern of metabolites formed by children may differ from that
observed in adults, as has been reported recently for sirolimus, a substrate of CYP3A4 and
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CYP3A5112. To our knowledge, the ontogeny of statin metabolism has not been investigated
to date.
CYP2C9 ontogeny is relevant to fluvastatin metabolism and also demonstrates a Group 3
developmental profile. Similar to CYP3A4, estimates of weight-adjusted drug clearance and
dose requirement are higher in young children than adults, but these differences largely
disappear when developmental differences in organ size are taken into consideration108.

Summary and Conclusions
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Based on the American Academy of Pediatrics guidelines, approximately 0.8% of
adolescents 12–17 years with dyslipidemia may qualify for pharmacological treatment. This
translates into approximately 200,000 12–17 year olds eligible for statin therapy113. Given
the ongoing childhood obesity epidemic, and the increased incidence of dyslipidemia
associated with obesity, it is anticipated that the number of children and adolescents
identified with dyslipidemia will continue to increase and some of these may ultimately
require statin therapy. With the potential for increased use of statins in children and
adolescents, it is imperative that we have improved understanding of the developmental
characteristics affecting the pharmacokinetics and pharmacodynamics of statins in these
pediatric populations. Simply extrapolating pediatric dosing guidelines from adult doseexposure-response relationships fails to recognize the complexity of growth and
developmental changes in pediatric patients, and the clinical implications for drug efficacy
or adverse drug effects6. Interestingly, a recent study demonstrated that genetic risk scores
derived from 95 SNVs associated with blood lipids in adults explained twice as much of the
total variance in HDL-cholesterol, LDL-cholesterol and total cholesterol in 3- to 6-year old
children compared to adults114. On the one hand, it is encouraging that genetic markers of
risk derived from adult data are also applicable to children, but the data also imply that
additional factors influence lipid levels in children and adults, and environmental factors
cannot be ignored.

Author Manuscript

From the perspective of statin treatment, as summarized above available data from adult
studies implicate hepatocellular uptake via OATP1B1 and CYP3A4-dependent metabolism
as critical determinants of statin disposition. This analysis also identified important
knowledge deficits relevant for pediatric investigations. First, the ontogeny of SLCO1B1 in
humans is unknown, and therefore it is not possible to predict the influence that
developmental differences in OATP1B1 expression may have on statin systemic exposure at
different ages/developmental stages. Second, without this information it is difficult to predict
the effect of allelic variation in SLCO1B1 on statin system exposure in pediatric populations
as illustrated by the limited pediatric data to date106, nor when genotype-phenotype
relationships observed in adults will become apparent in children. It is interesting to note in
this regard that genotype-phenotype relationships for ABCB1 were not apparent in children
<8 years of age, but were observed in children 8 years of age and older115. Thus, genotypeaided pharmocokinetic studies are warranted in children and adolescents to resolve this
matter and determine in age-related differences in the dose-exposure relationship are
present. Finally, modeling studies suggest that OATP1B1 activity is the primary determinant
of plasma statin concentration whereas intracellular statin concentrations are determine by
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CYP and efflux transporter activity62. Thus, one cannot ignore the potential for
developmental or pharmacogenetic differences in CYP3A4 activity to influence the
inhibitory effects of statins on cholesterol biosynthesis.
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The traditional model of clinical drug development is to investigate the effect of statins in
populations, and then attempt to apply the data to treat individual patients. The problem is
further complicated when the population experience is in adults, and the information is to be
applied to pediatric patients of different ages. Therefore, there is a need to conduct studies to
identify and quantify sources of inter-individual variability in statin disposition and response
for the management of dyslipidemias in children and adolescents. The challenge for the
future is address each of the knowledge deficits identified above to better characterize the
dose-exposure-response relationship in children and adolescents such that the design of
future clinical trials will be better informed, increasing the likelihood of clinically useful
data and avoiding the mistakes of the past116.
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Figure 1. Cholesterol Biosynthesis Pathway
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Statins as a class inhibit endogenous cholesterol production by competitive inhibition of
HMG-CoA reductase (HMGCR), which catalyzes conversion of HMG-CoA to mevalonate,
an early rate-limiting step in cholesterol synthesis. The effect of statins is shown in the
context of genes involved in the metabolism and transport of plasma lipoproteins that affect
atherosclerosis and cardiovascular disease risk. A more detailed description of individual
genes and gene products can be found at http://www.pharmgkb.org/pathway/PA2031
(accessed May 14, 2012). The figure is copyrighted by the Pharmacogenomics
Knowledgebase (PharmGKB; E.M. McDonagh, M. Whirl-Carrillo, Y. Garten, R.B. Altman
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and T.E. Klein. From pharmacogenomic knowledge acquisition to clinical applications: the
PharmGKB as a clinical pharmacogenomic biomarker resource. Biomarkers in Medicine
2011;5:795–806), and permission to reproduce it is provided by PharmGKB and Stanford
University. PharmGKB©.
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Figure 2. Genes involved in statin disposition
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Cellular uptake of statins is mediated by the SLCO and SLC gene families of transporters.
Once inside cells, phase 1 metabolism of the drugs is mediated by CYP members, of which
CYP3A4 appears to be most important, in general. Phase 2 conjugation by
glucuronosyltransferases (UGTs) is followed by cellular efflux by ABC cassette
transporters. Specific details for individual statins is provided in the text, and a more detailed
description of individual genes and gene products can be found at http://www.pharmgkb.org/
pathway/PA145011108 (accessed May 14, 2012). The figure is copyrighted by the
Pharmacogenomics Knowledgebase (PharmGKB; E.M. McDonagh, M. Whirl-Carrillo, Y.
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Garten, R.B. Altman and T.E. Klein. From pharmacogenomic knowledge acquisition to
clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource.
Biomarkers in Medicine 2011;5:795–806), and permission to reproduce it is provided by
PharmGKB and Stanford University. PharmGKB©.
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Drug Distribution of FDA Approved Statins
Statin (year of approval)

Phase 0

Phase 1

Phase 2

Phase 3

Lovastatin (1987)

Passive diffusion

3A4

UGT

BCRP

3A4

UGT

BCRP(lactone)

3A4 (minor)

UGT (minor)

MRP2

OATP1B1 (minor)
Simvastatin (1991)

Passive diffusion
OATP1B1 (minor)

Pravastatin (1991)

OATP1B1

MDR1 (minor)
BCRP (minor)
BSEP (minor)
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Fluvastatin (1993)

OATP1B1

2C9

?

BCRP

Atorvastatin (1996)

OATP1B1

3A4

UGT

BCRP

Rosuvastatin (2003)

OATP1B1

3A4 (minor)

UGT (minor)

BCRP

3A4 (minor)

UGT (minor)

MDR2

OATP1B3 (minor)
OATP2B1 (minor)
Pitavastatin (2009)

OATP1B1
OATP1B3 (minor)

BCRP
MRP2
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